Johns Hopkins registers Phase 2 trial of Revolution Medicines' daraxonrasib in biliary tract cancer
A new Phase 2 study will test daraxonrasib in KRAS-mutant biliary tract cancer patients who failed prior therapy, sponsored by Johns Hopkins with Revolution Medicines as collaborator.
This week brought a single new trial registration involving Revolution Medicines' daraxonrasib.
- A Phase 2 study titled "A Multi-Institutional Phase 2 Evaluation of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer" (NCT07793253) is not yet recruiting, with an estimated start of November 2026. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is the lead sponsor, with Revolution Medicines, Inc. and the Cholangiocarcinoma Foundation as collaborators.1 The trial will assess daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant biliary tract cancer who progressed on or could not tolerate first-line systemic therapy.1 The study plans to enroll 55 participants (estimated)1 and will use objective response rate as its primary outcome, defined as the proportion of patients achieving complete or partial response per RECIST v1.1.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.